Pure cardiac muscle cells, ready to transplant into a patient affected by heart disease.

That’s a goal for many cardiology researchers working with stem cells. Having a pure population of cardiac muscle cells is essential for avoiding tumor formation after transplantation, but has been technically challenging.

Researchers at Emory and Georgia Tech have developed a method for purifying cardiac muscle cells from stem cell cultures using molecular beacons.

Molecular beacons are tiny “instruments” that become fluorescent only when they find cells that have turned on certain genes. In this case, they target instructions to make a type of myosin, a protein found in cardiac muscle cells.

Doctors could use purified cardiac muscle cells to heal damaged areas of the heart in patients affected by heart attack and heart failure. In addition, the molecular beacons technique could have broad applications across regenerative medicine, because it could be used with other types of cells produced from stem cell cultures, such as brain cells or insulin-producing islet cells.

The results are published in the journal Circulation.

“Often, we want to generate a particular cell population from stem cells for introduction into patients,” says co-senior author Young-sup Yoon, MD, PhD, professor of medicine (cardiology) and director of stem cell biology at Emory University School of Medicine. “But the desired cells often lack a readily accessible surface marker, or that marker is not specific enough, as is the case for cardiac muscle cells. This technique could allow us to purify almost any type of cell.” 

Gang Bao, PhD, whose laboratory has pioneered the design and use of molecular beacons, is co-senior author. Bao is Robert A. Milton chair, Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. The first authors are Emory postdoctoral fellow Kiwon Ban, PhD and Georgia Tech graduate student Brian Wile.

Ban, Wile and their colleagues cultured stem cells with growth factors, which induced them to differentiate into clumps of spontaneously beating cardiac muscle cells. The experiments used embryonic stem cells or separately, induced pluripotent stem cells, from either mice or humans. For human cells, it takes about two weeks for cardiac muscle cells to form in large numbers.

Molecular beacons home in on messenger RNA produced by particular genes. The molecular beacons are designed to become fluorescent only when they find messenger RNA with the right genetic sequence. Using molecular beacons together with a flow cytometer, which sorts cells based on fluorescence, allowed researchers to pick out the cardiac muscle cells.

The purified cells could engraft into the damaged hearts of mice after a simulated heart attack, and the graft improved the heart’s pumping power (ejection fraction). Recovering animals that received no cells had their ejection fraction fall. When unpurified cells were grafted into mice, all the mice developed teratomas: tumors derived from the stem cells. Note: only mouse stem cells were transplanted into mice.

An important next step for developing purified cardiomyocytes as a therapy for heart diseases, Yoon says, is to engineer them into artificial tissues.

“In previous experiments with injected bare cells, investigators at Emory and elsewhere have found that a large proportion of the cells are washed away,” he says. “We need to engineer the cells into compatible biomaterials to enhance engraftment and retention.”

The research was supported by the National Heart Lung and Blood Institute (Center for Translational Cardiovascular Nanomedicine: HHSN268201000043C and R01HL088488), the National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK94346), the Atlanta Clinical Translational Science Institute, and the National Science Foundation (Emergent Behaviors of Integrated Cellular Systems: 0939511). Ban has an American Heart Association postdoctoral fellowship.

Reference: K. Ban et al. Purification of cardiomyocytes from differentiating pluripotent stem cells using molecular beacons targeting cardiomyocyte-specific mRNA Circulation (2013).